The burden of rare disease beyond patient counts

What comes after “How many patients?”

Patient numbers are essential when describing a rare disease program. They inform trial planning, access, and market assessment. They do not, by themselves, explain the burden borne by an individual patient.

Hutchinson–Gilford progeria syndrome (HGPS) illustrates this limitation. It affects a very small population, yet its effects begin early in life and are severe. Alongside the number of people needing treatment, an assessment should consider the onset of impairment, loss of function, and premature mortality.

Patient estimates also need context. Identified patients and estimated cases are different measures, as are HGPS and related progeroid conditions. Counts from different dates or definitions should not be presented as a single fixed population.

Measuring the burden of early death

Years of life lost (YLL) is one measure of premature mortality. It generally sums deaths at each age multiplied by the standard remaining life expectancy at that age. That differs from using a patient count or a single average age at death.

YLL makes the time lost through early death visible. It does not capture every dimension of pain, disability, caregiving, or daily life. Understanding disease burden also requires attention to how people live with the condition.

Interpreting the example of 400 people and 23,400 years

Consider a simple illustration. If the reference age is 73 and the assumed age at death is 14.5, the difference is 58.5 years. Multiplying by 400 gives 23,400 years. The example shows how an early death can represent a substantial loss of time.

It should not be presented as an estimate of annual HGPS YLL. A count of 400 living patients is not a count of deaths in one year. A reference age of 73 is also not an age-specific standard remaining life expectancy. Direct comparison with annual cancer deaths in another country would mix incompatible measures.

Comparisons between diseases need aligned geography, periods, death counts, and life-expectancy standards. That consistency is necessary if the results are to inform funding or health policy.

Why the wait for treatment matters

For a rapidly progressing disease, development time can affect the opportunity to benefit from treatment. It can change how long a person retains function, whether they can enter a trial, and their condition when a treatment becomes available.

Descriptions of accelerated aging in HGPS should not be converted into a clock with a fixed multiplier. A one-year treatment delay does not establish exactly seven years of biological damage. Natural-history data and clinical outcomes are needed to assess disease progression and the consequences of delay.

Where repurposing can contribute

Drug repurposing uses existing research and development evidence to investigate a new indication. The ability to use some prior work can make it a useful development option. It does not guarantee a fixed timeline, and safety and efficacy in the new population still require evaluation.

Lonafarnib was approved in the United States for HGPS in 2020, while other approaches, including gene editing, have been investigated. Gene-editing results in mice are an important research finding, but they do not directly establish human efficacy, safety, or a development schedule.

A repurposing assessment should describe the limitations of existing treatment, the function a new candidate aims to improve, and the evidence that can actually support its development. Speed matters, but it needs to be considered with expected benefit and the quality of the supporting evidence.

Considering patients and time together

This perspective applies beyond progeria. In pediatric rare disease, early mortality, functional decline, and the burden on patients and caregivers reveal needs that a population count can miss.

Social value and commercial viability also require distinct assessments. Patient numbers are a useful starting point. Severity, unmet need, access, and evidence-supported benefit are needed to explain research and investment priorities more fully.